MA42810A - Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue - Google Patents

Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue

Info

Publication number
MA42810A
MA42810A MA042810A MA42810A MA42810A MA 42810 A MA42810 A MA 42810A MA 042810 A MA042810 A MA 042810A MA 42810 A MA42810 A MA 42810A MA 42810 A MA42810 A MA 42810A
Authority
MA
Morocco
Prior art keywords
monosubstituted
dengue virus
virus replication
indole derivatives
derivatives used
Prior art date
Application number
MA042810A
Other languages
English (en)
Inventor
Dorothée Alice Marie-Eve Bardiot
Jean-François Bonfanti
Tim Hugo Maria Jonckers
Bart Rudolf Romanie Kesteleyn
Arnaud Didier M Marchand
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of MA42810A publication Critical patent/MA42810A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA042810A 2015-09-16 2016-09-15 Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue MA42810A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15185523 2015-09-16
EP16163472 2016-04-01

Publications (1)

Publication Number Publication Date
MA42810A true MA42810A (fr) 2018-07-25

Family

ID=56926217

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042810A MA42810A (fr) 2015-09-16 2016-09-15 Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue

Country Status (30)

Country Link
US (1) US10765662B2 (fr)
EP (1) EP3350162B1 (fr)
JP (2) JP7050666B2 (fr)
KR (1) KR102646174B1 (fr)
CN (1) CN108473422B (fr)
AU (1) AU2016324982B2 (fr)
CA (1) CA2996979C (fr)
CL (1) CL2018000696A1 (fr)
CO (1) CO2018003471A2 (fr)
CR (1) CR20180213A (fr)
DK (1) DK3350162T3 (fr)
EA (1) EA035663B1 (fr)
EC (1) ECSP18020055A (fr)
ES (1) ES2893298T3 (fr)
HK (1) HK1257842A1 (fr)
HR (1) HRP20211352T1 (fr)
HU (1) HUE055870T2 (fr)
IL (1) IL258043B (fr)
JO (1) JOP20160198B1 (fr)
LT (1) LT3350162T (fr)
MA (1) MA42810A (fr)
MX (1) MX2018003255A (fr)
NI (1) NI201800039A (fr)
PE (1) PE20181165A1 (fr)
PH (1) PH12018500576A1 (fr)
SI (1) SI3350162T1 (fr)
TW (1) TWI758255B (fr)
UA (1) UA122973C2 (fr)
UY (1) UY36903A (fr)
WO (1) WO2017046255A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MA49809A1 (fr) 2015-12-16 2021-08-31 Loxo Oncology Inc Composés utilisés comme inhibiteurs de kinase
EP3436436B1 (fr) 2016-03-31 2022-05-11 Janssen Pharmaceuticals, Inc. Dérivés substitués de l'indoline comme inhibiteurs du virus de la dengue
JP6888021B2 (ja) 2016-03-31 2021-06-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドール誘導体
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20180494A (es) * 2016-04-01 2019-01-29 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
JOP20180025B1 (ar) * 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) * 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20190531A (es) 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
KR102625988B1 (ko) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69830335T2 (de) * 1997-10-27 2006-02-02 Eli Lilly And Co., Indianapolis MORPHOLINO-N-ETHYL ESTER PRODROGEN VON INDOL sPLA 2 HEMMER
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
CA2468202A1 (fr) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Essais et mises en oeuvre permettant de determiner et de moduler une activite de liaison hsp90
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CN101103026A (zh) 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
US20060194835A1 (en) 2005-02-09 2006-08-31 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
PE20081897A1 (es) * 2007-03-29 2009-02-09 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
EP2293671A4 (fr) 2008-06-03 2012-03-21 Siga Technologies Inc Inhibiteurs à petites molécules pour le traitement et la prévention de l'infection par le virus de la dengue
BRPI0917394A2 (pt) * 2008-08-18 2019-09-24 Univ Yale moduladores de mif
EP2331499B1 (fr) 2008-08-19 2016-09-21 Janssen Pharmaceutica NV Antagonistes des récepteurs au froid activés par le menthol
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
CN102712632A (zh) 2010-01-15 2012-10-03 吉里德科学公司 黄病毒科病毒的抑制剂
JP2013523657A (ja) * 2010-03-26 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのインダゾリル‐ピリミジン
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
SI3201176T1 (sl) 2014-10-01 2019-05-31 Janssen Pharmaceuticals, Inc. Mono-ali di-substituirani derivati indola kot inhibitorji replikacije virusa denga
NO2721243T3 (fr) 2014-10-01 2018-10-20
ES2711117T3 (es) * 2014-10-01 2019-04-30 Janssen Pharmaceuticals Inc Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
JOP20150335B1 (ar) 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
RU2761212C2 (ru) 2015-11-03 2021-12-06 Зоэтис Сервисиз Ллс Полимерные композиты, полученные по способу золь-гель, и их применение
CA3019298C (fr) 2016-03-31 2023-08-29 Takeda Pharmaceutical Company Limited Compose heterocyclique
EP3436436B1 (fr) 2016-03-31 2022-05-11 Janssen Pharmaceuticals, Inc. Dérivés substitués de l'indoline comme inhibiteurs du virus de la dengue
JP6888021B2 (ja) 2016-03-31 2021-06-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドール誘導体
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN109069512B (zh) 2016-04-01 2022-06-14 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
MA43603A1 (fr) 2016-04-01 2019-03-29 Amgen Inc Récepteurs chimériques et leurs procédés d'utilisation
EP3436479A1 (fr) 2016-04-01 2019-02-06 Amgen Inc. Récepteurs chimères de flt3 et leurs procédés d'utilisation
CR20180494A (es) 2016-04-01 2019-01-29 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
KR102411744B1 (ko) 2016-04-01 2022-06-21 바스프 에스이 바이시클릭 화합물
IL303785A (en) 2016-04-01 2023-08-01 Kite Pharma Inc Chimeric antigen and T cell receptors and methods of use
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102625988B1 (ko) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
CR20190531A (es) 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue

Also Published As

Publication number Publication date
AU2016324982B2 (en) 2021-04-15
CL2018000696A1 (es) 2018-07-06
CR20180213A (es) 2018-06-27
EA035663B1 (ru) 2020-07-23
JP2018528220A (ja) 2018-09-27
JP2021181485A (ja) 2021-11-25
EP3350162B1 (fr) 2021-07-14
ES2893298T3 (es) 2022-02-08
EP3350162A1 (fr) 2018-07-25
IL258043A (en) 2018-05-31
AU2016324982A1 (en) 2018-03-15
EA201890722A1 (ru) 2018-09-28
NI201800039A (es) 2018-07-24
KR20180052672A (ko) 2018-05-18
JOP20160198B1 (ar) 2022-03-14
US10765662B2 (en) 2020-09-08
DK3350162T3 (da) 2021-10-04
LT3350162T (lt) 2021-09-27
KR102646174B1 (ko) 2024-03-08
CN108473422A (zh) 2018-08-31
IL258043B (en) 2021-08-31
WO2017046255A1 (fr) 2017-03-23
MX2018003255A (es) 2018-11-09
CN108473422B (zh) 2021-06-15
TW201722913A (zh) 2017-07-01
CA2996979A1 (fr) 2017-03-23
JP7050666B2 (ja) 2022-04-08
UY36903A (es) 2017-03-31
HRP20211352T1 (hr) 2022-02-04
US20180256545A1 (en) 2018-09-13
SI3350162T1 (sl) 2021-11-30
CO2018003471A2 (es) 2018-07-10
CA2996979C (fr) 2024-01-30
PE20181165A1 (es) 2018-07-19
UA122973C2 (uk) 2021-01-27
HUE055870T2 (hu) 2021-12-28
PH12018500576A1 (en) 2018-10-15
ECSP18020055A (es) 2018-04-30
HK1257842A1 (zh) 2019-11-01
TWI758255B (zh) 2022-03-21

Similar Documents

Publication Publication Date Title
MA42810A (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA44502A (fr) Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA48987A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA48943A (fr) Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
DK3328843T3 (da) 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
DK3362445T3 (da) Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
DK3294738T3 (da) Mono- og disubstituerede indolderivater som inhibitorer af replikation af denguevirus
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
DK3330259T3 (da) 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne